Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Regeneron Pharmaceuticals Inc REGN

Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular... see more

Current News (NDAQ:REGN)

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

GlobeNewswire 4 days ago

Biotech's Next Wave May Already be in Motion

GlobeNewswire 5 days ago

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

GlobeNewswire 7 days ago

Regeneron Reports First Quarter 2026 Financial and Operating Results

GlobeNewswire 13 days ago

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

GlobeNewswire April 23, 2026

Otarmeni(TM) (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.

GlobeNewswire April 23, 2026

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

GlobeNewswire April 22, 2026

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

GlobeNewswire April 21, 2026

Regeneron Announces Investor Conference Presentations

GlobeNewswire April 20, 2026
View More News ››

Opinion & Analysis (NDAQ:REGN)

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

Streetwise Reports March 18, 2020

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Streetwise Reports September 24, 2019

Phase 3 trial for Inovio's VGX-3100 in cervical dysplasia gets FDA go-ahead

The Life Sciences Report June 16, 2017

Inovio moves forward on brain cancer and cancers caused by HPV; Zika and Ebola vaccines also advance

The Life Sciences Report May 18, 2017

Why the election is not as relevant to drug stocks as you might believe

The Life Sciences Report November 4, 2016

Let volatility power your micro-cap biotechs

The Life Sciences Report April 28, 2016
View More Opinion ››

Bullboard Posts (NDAQ:REGN)

RE:Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): A Diversified

JP Morgan has a high tarket on REGN I bought in at $696 this week now $736 . It has upside for sure.
helpful1 - December 11, 2025

REGN: Antibodies and Disruption

Regeneron’s monoclonal antibodies are changing the game, and MYNZ is disrupting diagnostics in the best way possible. Innovation rules.
Trader19Swift - November 26, 2024

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): A Diversified

http://beyondspx.com/2024/07/31/regeneron-pharmaceuticals-inc-nasdaqregn-a-diversified-powerhouse-delivering-consistent-growth/
MikeTester - August 2, 2024

Just added REGN

Just added 1/2 position of REGN.   Will add a few more next month.
Mmb060 - April 20, 2023

Bonvoyage12.....Lying Pumper

Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on...
Mil_Man54 - December 26, 2020

Vaccine Stocks - Can the President Overrule the FDA?

An approval cycle that typically takes years is being expedited. In the case of the 2020 pandemic, the FDA  has shortened standard...
schoolofrock - October 7, 2020
View more Bullboard ››

SEGO Resources Inc.

SEGO Resources Inc.

Sego Resources Inc., an exploration stage company, engages in the acquisition, exploration, and evaluation of mineral ...
View More »

Podcasts